AOCNP (Advanced Oncology Certified Nurse Practitioner) WITH 200 CORRECT ACTUAL QUESTIONS AND CORRECTLY WELL DEFINED ANSWERS LATEST ALREADY GRADED A+ (2025/2026)

AOCNP (Advanced Oncology Certified Nurse Practitioner) WITH 200 CORRECT ACTUAL QUESTIONS AND CORRECTLY WELL DEFINED ANSWERS LATEST ALREADY GRADED A+ (2025/2026) Question 1 A 62-year-old woman with stage II breast cancer is starting dose-dense doxorubicin and cyclophosphamide. Her baseline echocardiogram shows an LVEF of 58%. Which action is most appropriate before cycle 2? A. Administer cycle 2 without further cardiac testing. B. Repeat echocardiogram only if she develops symptoms. C. Hold chemotherapy and start carvedilol. D. Order a baseline troponin and BNP before each cycle. Correct Answer: A. Administer cycle 2 without further cardiac testing. Rationale: Routine cardiac monitoring with echocardiogram is typically performed at baseline and then as clinically indicated or when the cumulative doxorubicin dose approaches 400–450 mg/m². In a patient with normal baseline LVEF and no symptoms, repeating the echo before every cycle is not standard. Repeating it only with symptoms (B) is too passive. Holding for prophylactic carvedilol (C) is not evidence-based in asymptomatic patients. Troponin/BNP (D) are not standard for routine anthracycline monitoring. Tested Concept: Anthracycline cardiotoxicity monitoring schedule. Difficulty: Moderate --- Question 2 A 45-year-old male with diffuse large B-cell lymphoma receiving R-CHOP develops acute flank pain, nausea, and oliguria 18 hours after cycle 1. Labs: K 6.5, Phos 8.0, Ca 6.8, uric acid 16 mg/dL. What is the most appropriate next step? A. IV normal saline at 200 mL/hr and allopurinol. B. IV normal saline at 200 mL/hr and rasburicase. C. IV normal saline at 200 mL/hr and sodium bicarbonate. D. Hemodialysis. Correct Answer: B. IV normal saline at 200 mL/hr and rasburicase. Rationale: The patient has established Tumor Lysis Syndrome with significant hyperuricemia and acute kidney injury. Rasburicase provides rapid enzymatic breakdown of existing uric acid. Allopurinol (A) prevents new uric acid formation but does not reduce existing levels quickly. Sodium bicarbonate (C) is controversial and may worsen calcium phosphate precipitation. Hemodialysis (D) is reserved for refractory hyperkalemia or renal failure not responding to medical management; it is not the first step. Tested Concept: TLS management with rasburicase. Difficulty: Moderate --- Question 3 A patient on FOLFOX for colon cancer reports tingling in his fingers that occurs only during the infusion and resolves within 48 hours. He has no functional limitations. How should the AOCNP grade this neuropathy? A. Grade 1 acute. B. Grade 2 acute. C. Grade 1 chronic. D. Grade 2 chronic. Correct Answer: A. Grade 1 acute. Rationale: Acute oxaliplatin neuropathy is cold-induced, transient, and resolves between cycles. Grade 1 indicates paresthesias without functional impairment. Chronic neuropathy persists between cycles. Since symptoms resolve completely and do not affect function, this is Grade 1 acute neuropathy. Tested Concept: Oxaliplatin acute neuropathy grading. Difficulty: Easy --- Question 4 A patient on osimertinib for EGFR-mutant NSCLC develops acute-onset dyspnea, dry cough, and hypoxia. CT chest shows diffuse ground-glass opacities. What is the priority action? A. Administer empiric antibiotics and continue osimertinib. B. Hold osimertinib, start high-dose corticosteroids, and obtain bronchoscopy. C. Reduce osimertinib to 40 mg and monitor. D. Continue osimertinib and add supplemental oxygen. Correct Answer: B. Hold osimertinib, start high-dose corticosteroids, and obtain bronchoscopy. Rationale: This presentation is highly suspicious for osimertinib-induced ILD. The drug must be held immediately. Corticosteroids are the mainstay of treatment. Bronchoscopy may be needed to rule out infection. Continuing or reducing the drug (A, C, D) would worsen ILD and is contraindicated. Tested Concept: Osimertinib-induced ILD management. Difficulty: Difficult --- Question 5 A 52-year-old woman with HER2+ metastatic breast cancer is receiving trastuzumab, pertuzumab, and paclitaxel. Her baseline LVEF was 60%. At 6 months, her LVEF drops to 45%. What is the best next step? A. Continue therapy and monitor symptoms. B. Hold trastuzumab and pertuzumab, start an ACE inhibitor, and repeat LVEF in 3 weeks. C. Reduce trastuzumab dose by 50% and continue pertuzumab. D. Discontinue all HER2 therapy permanently. Correct Answer: B. Hold trastuzumab and pertuzumab, start an ACE inhibitor, and repeat LVEF in 3 weeks. Rationale: A significant drop in LVEF (10% absolute or below 50%) warrants holding HER2 therapy, initiating cardioprotective medications (ACE inhibitor or beta-blocker), and reassessing LVEF in 3–4 weeks. If recovery occurs, therapy may be resumed. Permanent discontinuation (D) is reserved for symptomatic heart failure or no recovery. Tested Concept: HER2 therapy cardiotoxicity management. Difficulty: Difficult --- Question 6 A patient with acute myeloid leukemia is about to start induction chemotherapy. Which laboratory values are essential to assess TLS risk before treatment? A. LDH, uric acid, creatinine, potassium, phosphorus, calcium. B. Hemoglobin, platelets, ANC. C. Liver function tests and albumin. D. PT/INR and aPTT. Correct Answer: A. LDH, uric acid, creatinine, potassium, phosphorus, calcium. Rationale: TLS risk assessment requires baseline uric acid, electrolytes (K, Phos, Ca), renal function (creatinine), and LDH (tumor burden marker). CBC (B), LFTs (C), and coagulation studies (D) are relevant to other aspects of care but not TLS risk stratification. Tested Concept: TLS baseline laboratory assessment. Difficulty: Easy --- Question 7 A patient receiving oxaliplatin reports throat tightness and difficulty swallowing when drinking cold beverages. His motor exam and ADLs are normal. What is the appropriate patient education? A. "This is a sign of anaphylaxis; carry an EpiPen." B. "Avoid cold drinks, cold air, and cold objects; this usually resolves after each cycle." C. "We need to reduce your oxaliplatin dose by 25%." D. "You should switch to a non-platinum regimen." Correct Answer: B. "Avoid cold drinks, cold air, and cold objects; this usually resolves after each cycle." Rationale: Pharyngolaryngeal dysesthesia is a classic acute oxaliplatin neuropathy triggered by cold. It is not anaphylaxis (A). Dose reduction (C) is not indicated for Grade 1 acute neuropathy. Switching agents (D) is unnecessary. Tested Concept: Oxaliplatin acute neuropathy patient education. Difficulty: Moderate --- Question 8 Which chemotherapy agent requires a lifetime cumulative dose limit of 450–550 mg/m² to prevent cardiomyopathy? A. Oxaliplatin. B. Cisplatin. C. Doxorubicin. D. Paclitaxel. Correct Answer: C. Doxorubicin. Rationale: Doxorubicin is an anthracycline with dose-dependent cardiotoxicity. The lifetime cumulative max is 450–550 mg/m². Oxaliplatin has a cumulative limit for neuropathy (~750–850 mg/m²). Cisplatin has nephrotoxicity and ototoxicity limits. Paclitaxel has no cumulative cardiotoxicity limit. Tested Concept: Anthracycline cumulative dose limits. Difficulty: Easy --- Question 9 A patient with Burkitt's lymphoma develops TLS. Which electrolyte abnormality is most immediately life-threatening? A. Hyperuricemia. B. Hyperphosphatemia. C. Hypocalcemia. D. Hyperkalemia. Correct Answer: D. Hyperkalemia. Rationale: Hyperkalemia can cause fatal cardiac arrhythmias and is the most acutely life-threatening abnormality in TLS. Hyperuricemia (A) can cause AKI but is slower to kill. Hyperphosphatemia (B) and hypocalcemia (C) are serious but not immediately arrhythmogenic. Tested Concept: TLS life-threatening electrolyte priorities. Difficulty: Moderate --- Question 10 A patient on trastuzumab develops a new nonproductive cough and dyspnea. Chest CT shows bilateral interstitial infiltrates. No infection is found. What is the most likely diagnosis? A. Trastuzumab-induced cardiotoxicity. B. Trastuzumab-induced interstitial lung disease. C. Pulmonary embolism. D. Bacterial pneumonia. Correct Answer: B. Trastuzumab-induced interstitial lung disease. Rationale: While less common than cardiotoxicity, trastuzumab can cause ILD. The presentation of cough, dyspnea, and interstitial infiltrates in the absence of infection makes ILD most likely. Cardiotoxicity (A) would show reduced LVEF and pulmonary edema, not infiltrates. PE (C) would show wedge-shaped opacity or normal CT. Pneumonia (D) would typically have fever and leukocytosis. Tested Concept: Trastuzumab-associated ILD. Difficulty: Moderate --- Question 11 A patient's pre-chemotherapy labs show ANC 400/mm³ and platelets 25,000/mm³. What is the appropriate action regarding chemotherapy administration? A. Proceed with chemotherapy at full dose. B. Proceed with chemotherapy and administer G-CSF prophylactically. C. Delay chemotherapy until ANC 1,000 and platelets 50,000. D. Administer chemotherapy at 50% dose. Correct Answer: C. Delay chemotherapy until ANC 1,000 and platelets 50,000. Rationale: Severe myelosuppression (Grade 4 neutropenia and thrombocytopenia) is an absolute contraindication to chemotherapy administration. Chemotherapy should be delayed until counts recover. G-CSF (B) is appropriate after holding chemo to accelerate recovery, but the question asks about chemotherapy administration. Tested Concept: Myelosuppression and chemotherapy dosing. Difficulty: Moderate --- Question 12 A patient with NSCLC on osimertinib develops a widespread acneiform rash on the face and chest. What is the most appropriate intervention? A. Hold osimertinib until rash resolves. B. Reduce osimertinib dose to 40 mg. C. Prescribe topical corticosteroids and oral doxycycline; continue osimertinib. D. Discontinue osimertinib and switch to afatinib. Correct Answer: C. Prescribe topical corticosteroids and oral doxycycline; continue osimertinib. Rationale: Rash is a common EGFR-TKI side effect that is manageable with supportive care. Continuing the drug with topical steroids and oral antibiotics (doxycycline or minocycline) is standard. Holding or reducing (A, B) is reserved for severe (Grade 3–4) rash. Switching (D) is unnecessary and would expose the patient to different toxicities. Tested Concept: EGFR-TKI rash management. Difficulty: Easy --- Question 13 A patient on FOLFOX has completed 10 cycles and now reports that the numbness in his feet is so severe that he has fallen twice. He cannot feel the floor. How should the neuropathy be graded? A. Grade 1 chronic. B. Grade 2 chronic. C. Grade 3 chronic. D. Grade 4 chronic. Correct Answer: C. Grade 3 chronic. Rationale: Grade 3 neuropathy interferes with activities of daily living (ADLs), including walking and balance. Falls are a clear sign of functional impairment, defining Grade 3. Grade 4 is life-threatening (e.g., respiratory muscle paralysis). Grade 1 = no functional impairment; Grade 2 = interferes with function but not ADLs. Tested Concept: Chronic oxaliplatin neuropathy grading. Difficulty: Moderate --- Question 14 In TLS, hypocalcemia occurs secondary to which process? A. Calcium excretion by the kidneys. B. Binding of calcium to phosphate released from lysed cells. C. Parathyroid hormone suppression. D. Vitamin D deficiency. Correct Answer: B. Binding of calcium to phosphate released from lysed cells. Rationale: Rapid cell lysis releases intracellular phosphate, which binds to serum calcium to form calcium phosphate precipitates, leading to hypocalcemia. This is not due to renal excretion (A), PTH (C), or vitamin D (D). Tested Concept: TLS pathophysiology. Difficulty: Moderate --- Question 15 A patient with HER2+ breast cancer is starting trastuzumab. Which baseline cardiac test is recommended? A. Electrocardiogram (ECG). B. Chest X-ray. C. Echocardiogram or MUGA scan. D. Cardiac stress test. Correct Answer: C. Echocardiogram or MUGA scan. Rationale: LVEF assessment via echocardiogram or MUGA is required before initiating trastuzumab. ECG (A) is not sufficient. CXR (B) is for pulmonary issues. Stress test (D) is not routine for baseline assessment. Tested Concept: Trastuzumab baseline cardiac assessment. Difficulty: Easy --- Question 16 A patient receiving cisplatin-based chemotherapy develops acute kidney injury. In addition to hydration, which agent should be considered to reduce nephrotoxicity? A. Mannitol. B. Amifostine. C. Mesna. D. Leucovorin. Correct Answer: B. Amifostine. Rationale: Amifostine is a cytoprotective agent that reduces cisplatin-induced nephrotoxicity. Mannitol (A) is used for forced diuresis but not standard. Mesna (C) is for hemorrhagic cystitis from ifosfamide/cyclophosphamide. Leucovorin (D) is for methotrexate rescue. Tested Concept: Cisplatin nephrotoxicity prevention. Difficulty: Moderate --- Question 17 A patient on FOLFOX reports Grade 2 chronic neuropathy affecting her ability to write. What is the recommended dose modification for oxaliplatin? A. No change. B. Reduce by 25%. C. Reduce by 50%. D. Discontinue permanently. Correct Answer: B. Reduce by 25%. Rationale: Grade 2 chronic neuropathy (functional impairment not affecting ADLs) warrants a 25% dose reduction. Grade 3 (ADL impairment) warrants discontinuation. Grade 1 requires no change. Grade 4 is permanent discontinuation.